AC Immune reports 12-month interim data from ABATE trial of ACI-24
The Phase 1b/2 trial showed antibody dose response with no ARIA-E across the first three Alzheimer's cohorts, while a fourth cohort testing an added adjuvant is underway.
SEC filing
Latest
Tuesday, June 30
Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody study
Tenax and Orion finalize supply pact and sixth amendment for oral levosimendan
The June 29, 2026 filing details manufacturing, term, and termination provisions alongside an extended 2035 US approval deadline.
SEC filing
Monday, June 29
EU approves Enhertu as first tumor-agnostic HER2-directed ADC
The European Commission cleared Enhertu for previously treated HER2-positive metastatic solid tumors, triggering a $25 million milestone payment to Daiichi Sankyo.
SEC filing
Genmab reports positive Phase 3 results for epcoritamab plus lenalidomide in DLBCL
The EPCORE DLBCL-4 trial hit its primary endpoint, showing statistically significant improvement in progression-free survival for relapsed or refractory DLBCL patients.
SEC filing
BioCryst to close Birmingham research site, ends internal discovery programs
The company also finished enrollment in its Phase 3 HAE trial and cut 2026 expense guidance to $420-$440 million from $450-$470 million.
SEC filing
Evommune's EVO756 fails primary endpoint in Phase 2b urticaria trial
The company will stop developing EVO756 for chronic spontaneous urticaria but continue testing it in atopic dermatitis and migraine.
SEC filing
Abivax reports Part 2 maintenance data for obefazimod in ulcerative colitis
The company said the results strengthen its safety database ahead of a planned fourth-quarter 2026 NDA submission for obefazimod in UC.
SEC filing
Neurogene reports 30-month data for NGN-401 in Rett syndrome trial
All 10 participants in the Phase 1/2 trial gained developmental milestones with no plateau through 30 months, as the Embolden registrational trial completes dosing.
SEC filing
Zymeworks-Theravance merger includes new CVR tied to ampreloxetine monetization
The 8-K filing details a contingent value right giving Theravance shareholders a share of future ampreloxetine proceeds, plus termination fee terms, alongside the previously announced $929 million cash deal.
SEC filing
NeuroSense says Phase 2b ALS trial hit primary TDP-43 endpoint
NeuroSense reported that its PARADIGM study showed a statistically significant reduction in TDP-43 with PrimeC compared to placebo at Day 180.
SEC filing
Larimar submits first BLA module for nomlabofusp in Friedreich's ataxia, reports open-label data
FDA said the company's existing data package appears sufficient to support a BLA seeking accelerated approval based on skin frataxin as a surrogate endpoint.
SEC filing
Zymeworks to acquire Theravance Biopharma for $17.00 per share plus CVR
The deal, announced June 29, 2026, values Theravance Biopharma at roughly $929 million and adds a contingent payout tied to ampreloxetine.
SEC filing
BeyondSpring discloses finalized pay package for new CEO Min Qiu
An amended SEC filing sets Qiu's salary, bonus target, stock options, and severance terms tied to his June 4, 2026 appointment.
SEC filing
Cadrenal names John Sharp interim CFO, board reshuffles after director resigns
Cadrenal Therapeutics installed a new interim finance chief through its outside consulting firm and rearranged board classes following a director's departure.
SEC filing
Tenaya Therapeutics names Eric Hyllengren as new CFO effective July 13, 2026
The clinical-stage heart disease biotech also disclosed the retirement of Tomohiro Higa, its Senior Vice President, Finance, in the third quarter of 2026.
SEC filing
REGENXBIO doses first patient in Phase IIb/III diabetic retinopathy trial, triggers $100M payment
The suprachoroidal delivery study of sura-vec unlocks a milestone payment from AbbVie under the companies' 2021 collaboration deal.
SEC filing
Agomab Spain registers Phase 1 mass balance trial of ontunisertib in healthy volunteers
Inhibikase completes annual meeting filings, board elections finalized
The company's June 26 certificate amendment limiting officer liability is now effective, following stockholder votes at its 2026 annual meeting.
SEC filing
RedHill Biopharma expands at-the-market offering capacity by $2.128 million
The filing, dated June 29, 2026, raises the amount of ADSs RedHill can sell under its existing Wainwright sales agreement, citing thin public float rules.
SEC filing
Protara Therapeutics' chief medical officer resigns effective June 26, 2026
Leonardo Viana Nicacio's responsibilities will be absorbed by two other executives as the company continues clinical development.
SEC filing
Satellos wins FDA Fast Track for SAT-3247 in Duchenne muscular dystrophy
The designation adds to existing Orphan Drug and Rare Pediatric Disease status as two Phase 2 studies continue, with more data expected in the second half of 2026.
SEC filing
Decoy Therapeutics announces private placement financing of up to $21 million
The company said it expects roughly $3.5 million at closing, with milestone warrants that could add up to $17.5 million more.
SEC filing
FibroBiologics closes $3.0 million private placement priced at-the-market
The Houston biotech sold shares or pre-funded warrants and accompanying warrants at $0.735 per unit, with warrants carrying potential proceeds of about $6.0 million more if fully exercised.
SEC filing (2)
Tonix enrolls first patient in Phase 2 depression trial of TNX-102 SL
The trial tests TONMYA's active ingredient as a standalone treatment for major depressive disorder, with results expected on a six-week depression rating scale.
SEC filing
CHMP backs Datroway for first-line TNBC treatment in EU
AstraZeneca and Daiichi Sankyo's antibody drug conjugate received a positive EU opinion based on Phase III overall survival and progression-free survival data.
SEC filing
Tenax Therapeutics amends executive pay deals, adopts new severance plans
The board approved severance changes for CEO Christopher Giordano and two other executives while creating separate change-in-control and severance plans for other employees.
SEC filing
United Therapeutics shareholders approve 2026 stock incentive plan at annual meeting
At its June 26, 2026 annual meeting, United Therapeutics investors backed a new equity plan, re-elected all twelve directors, and ratified the company's auditor.
SEC filing
argenx registers Phase 2a empasiprubart trial in gMG; adimanebart PK study recruiting
Rhythm Pharmaceuticals is collaborator on new German real-world setmelanotide study in BBS
Cybin's Helus Pharma reports FY2026 results, Phase 3 MDD trial past 88% enrollment
The company posted a wider annual net loss alongside progress on its HLP003 depression program and a new HLP004 anxiety readout.
SEC filing
Rani Therapeutics names Nicholas Maestas as new chief financial officer
The appointment, effective June 29, 2026, succeeds Svai Sanford, who had previously announced plans to step down.
SEC filing
4D Molecular Therapeutics secures up to $200 million loan facility from Hercules Capital
The gene therapy company entered a senior secured term loan agreement on June 24, 2026, with an initial $20 million tranche drawn at closing and additional tranches tied to milestones.
SEC filing
NovaBridge Biosciences names Srishti Gupta as CEO, succeeding Sean Fu
The clinical-stage biopharma said Gupta, formerly CEO of Idorsia, will take over July 1, 2026, as the company pushes givastomig and VIS-101 toward registration.
SEC filing
Emergent BioSolutions gets $52.7 million ACAM2000 contract modification from ASPR
The modification exercises Option Year 7 under Emergent's existing 10-year ASPR contract, with deliveries due in June and December 2026.
SEC filing
InMune Bio posts results for Phase 2 XPro1595 trial in early Alzheimer's disease
Replimune's RP1 BLA resubmission accepted by FDA; adcomm expected late July
Replimune reported fiscal Q4 and full-year 2026 results and said the FDA accepted its resubmitted RP1 melanoma application with an August 2, 2026 goal date.
SEC filing
FDA approves labeling supplement for Janssen's Erleada (apalutamide)
Friday, June 26
FDA approves Viridian's Lumvoa for thyroid eye disease
Viridian Therapeutics said the FDA approved Lumvoa (veligrotug-vvze) on June 26, 2026, and plans to launch the drug immediately.
SEC filing